BridgeBio Pharma, (Germany) Performance
| 2CL Stock | EUR 64.46 2.00 3.01% |
On a scale of 0 to 100, BridgeBio Pharma, holds a performance score of 11. The firm shows a Beta (market volatility) of 0.39, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BridgeBio Pharma,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding BridgeBio Pharma, is expected to be smaller as well. Please check BridgeBio Pharma,'s downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether BridgeBio Pharma,'s price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BridgeBio Pharma are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, BridgeBio Pharma, reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | How dovish Fed policy supports BridgeBio Pharma Inc. stock - Weekly Trend Summary Smart Money Movement Alerts - newser.com | 11/14/2025 |
2 | How Investors May Respond To BridgeBio Pharma Strong Attruby Sales, Wider Losses, And CEO Stock Sale - simplywall.st | 12/10/2025 |
3 | BridgeBio Pharma stock hits all-time high at 77.32 By Investing.com - Investing.com Nigeria | 12/22/2025 |
4 | The biotech scorecard for the first quarter 26 stock-moving events to watch - statnews.com | 01/05/2026 |
5 | A Look At BridgeBio Pharma Valuation After New ATTR-CM, LGMD2IR9 And TTR Antibody Updates - simplywall.st | 01/14/2026 |
6 | BridgeBio Pharma Issues New Convertible Notes and Repurchases Stock - TipRanks | 01/21/2026 |
7 | BridgeBio Pharma stock initiated with Overweight rating by Barclays - Investing.com | 01/28/2026 |
8 | BridgeBio Pharma, Inc. Stock Analysis Eyeing a 20.55 percent Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews | 02/02/2026 |
BridgeBio |
BridgeBio Pharma, Relative Risk vs. Return Landscape
If you would invest 5,414 in BridgeBio Pharma on November 6, 2025 and sell it today you would earn a total of 1,032 from holding BridgeBio Pharma or generate 19.06% return on investment over 90 days. BridgeBio Pharma is currently producing 0.3161% returns and takes up 2.2556% volatility of returns over 90 trading days. Put another way, 20% of traded stocks are less volatile than BridgeBio, and 94% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BridgeBio Pharma, Target Price Odds to finish over Current Price
The tendency of BridgeBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 64.46 | 90 days | 64.46 | about 23.19 |
Based on a normal probability distribution, the odds of BridgeBio Pharma, to move above the current price in 90 days from now is about 23.19 (This BridgeBio Pharma probability density function shows the probability of BridgeBio Stock to fall within a particular range of prices over 90 days) .
BridgeBio Pharma, Price Density |
| Price |
Predictive Modules for BridgeBio Pharma,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BridgeBio Pharma,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BridgeBio Pharma, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BridgeBio Pharma, is not an exception. The market had few large corrections towards the BridgeBio Pharma,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BridgeBio Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BridgeBio Pharma, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.32 | |
β | Beta against Dow Jones | 0.39 | |
σ | Overall volatility | 4.19 | |
Ir | Information ratio | 0.12 |
BridgeBio Pharma, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BridgeBio Pharma, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BridgeBio Pharma, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 353.78 M. Net Loss for the year was (495.27 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. | |
| BridgeBio Pharma has accumulated about 837.66 M in cash with (470.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59. | |
| Over 95.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: BridgeBio Pharma, Inc. Stock Analysis Eyeing a 20.55 percent Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews |
BridgeBio Pharma, Fundamentals Growth
BridgeBio Stock prices reflect investors' perceptions of the future prospects and financial health of BridgeBio Pharma,, and BridgeBio Pharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BridgeBio Stock performance.
| Return On Asset | -0.43 | ||||
| Profit Margin | (2.25) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 13.68 B | ||||
| Shares Outstanding | 191.63 M | ||||
| Price To Sales | 36.22 X | ||||
| Revenue | 353.78 M | ||||
| EBITDA | (573.1 M) | ||||
| Cash And Equivalents | 837.66 M | ||||
| Cash Per Share | 5.59 X | ||||
| Total Debt | 1.4 B | ||||
| Debt To Equity | 4.61 % | ||||
| Book Value Per Share | (8.51) X | ||||
| Cash Flow From Operations | (470.42 M) | ||||
| Earnings Per Share | (3.57) X | ||||
About BridgeBio Pharma, Performance
By analyzing BridgeBio Pharma,'s fundamental ratios, stakeholders can gain valuable insights into BridgeBio Pharma,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BridgeBio Pharma, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BridgeBio Pharma, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. BRIDGEBIO PHARMA operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 385 people.Things to note about BridgeBio Pharma, performance evaluation
Checking the ongoing alerts about BridgeBio Pharma, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BridgeBio Pharma, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 353.78 M. Net Loss for the year was (495.27 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. | |
| BridgeBio Pharma has accumulated about 837.66 M in cash with (470.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59. | |
| Over 95.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: BridgeBio Pharma, Inc. Stock Analysis Eyeing a 20.55 percent Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews |
- Analyzing BridgeBio Pharma,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BridgeBio Pharma,'s stock is overvalued or undervalued compared to its peers.
- Examining BridgeBio Pharma,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BridgeBio Pharma,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of BridgeBio Pharma,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BridgeBio Pharma,'s stock. These opinions can provide insight into BridgeBio Pharma,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma,'s price analysis, check to measure BridgeBio Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma, is operating at the current time. Most of BridgeBio Pharma,'s value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma,'s price. Additionally, you may evaluate how the addition of BridgeBio Pharma, to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |